In the literature review we described studies, the main purpose of which was to distribute bladder tumors by molecular subtypes. A similar classification has long been actively used in the treatment of breast cancer. The pioneering work in the molecular subtypes of bladder cancer includes the work by Lund group, the TCGA (The Cancer Genome Atlas) project, the MD Anderson study. We have also included data on attempts to apply molecular taxonomy of bladder cancer in treatment
Therapeutic decisions for muscle-invasive bladder cancer (MIBC) are largely based on histopathologic...
Bladder Cancer is the 4th most commonly diagnosed cancer in men and the 8th most deadly. While non-m...
The precise classification of tumors into relevant molecular subtypes will facilitate both future re...
Decisions in the treatment of bladder cancer today are based on clinical and pathological risk varia...
Urothelial carcinoma of the bladder is a common malignancy causing an estimated 150,000 deaths per y...
Therapeutic decisions for breast cancer are increasingly becoming based on subtype-specific gene exp...
Bladder cancer is one of the most common malignancies world-wide, and in Sweden approximately 3000 c...
Comparative analysis showed that bladder cancer classification systems identify overlapping subtypes...
The advent of Omics technologies has been key to the molecular subclassification of urothelial bladd...
Treatment of bladder cancer patients depends on precise diagnosis. Molecular subtyping by gene expre...
Several molecular and genetic studies have provided new perspectives on the histologic classificatio...
Bladder cancer is a heterogeneous disease that is not depicted by current classification systems. It...
Context Recent whole genome mRNA expression profiling studies revealed that bladder cancers can be g...
Bladder cancer is one of the most prevalent cancers worldwide. Unfortunately, there have been few ad...
Molecular subtyping may inform on prognosis and treatment response in bladder cancer. However, intra...
Therapeutic decisions for muscle-invasive bladder cancer (MIBC) are largely based on histopathologic...
Bladder Cancer is the 4th most commonly diagnosed cancer in men and the 8th most deadly. While non-m...
The precise classification of tumors into relevant molecular subtypes will facilitate both future re...
Decisions in the treatment of bladder cancer today are based on clinical and pathological risk varia...
Urothelial carcinoma of the bladder is a common malignancy causing an estimated 150,000 deaths per y...
Therapeutic decisions for breast cancer are increasingly becoming based on subtype-specific gene exp...
Bladder cancer is one of the most common malignancies world-wide, and in Sweden approximately 3000 c...
Comparative analysis showed that bladder cancer classification systems identify overlapping subtypes...
The advent of Omics technologies has been key to the molecular subclassification of urothelial bladd...
Treatment of bladder cancer patients depends on precise diagnosis. Molecular subtyping by gene expre...
Several molecular and genetic studies have provided new perspectives on the histologic classificatio...
Bladder cancer is a heterogeneous disease that is not depicted by current classification systems. It...
Context Recent whole genome mRNA expression profiling studies revealed that bladder cancers can be g...
Bladder cancer is one of the most prevalent cancers worldwide. Unfortunately, there have been few ad...
Molecular subtyping may inform on prognosis and treatment response in bladder cancer. However, intra...
Therapeutic decisions for muscle-invasive bladder cancer (MIBC) are largely based on histopathologic...
Bladder Cancer is the 4th most commonly diagnosed cancer in men and the 8th most deadly. While non-m...
The precise classification of tumors into relevant molecular subtypes will facilitate both future re...